Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 5:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 555 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Thrombosis, Venous Clear all
Completed No phase listed Observational Results available

Registry of AngioJet Use in the Peripheral Vascular System

NCT01086215
View directory record Official record
Conditions
Peripheral Vascular Disease, Embolism and Thrombosis, Venous Thrombosis
Interventions
Not listed
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
32
States / cities
Glendale, Arizona • Phoenix, Arizona • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2014 · Synced Oct 24, 2026, 5:11 PM EDT
Completed Phase 3 Interventional

Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin

NCT00329628
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (BAY59-7939), Enoxaparin
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
4,541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
13
States / cities
Birmingham, Alabama • Northport, Alabama • Phoenix, Arizona + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2014 · Synced Oct 24, 2026, 5:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Participants

NCT02912234
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Apixaban, Clarithromycin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Oct 24, 2026, 5:11 PM EDT
Completed Not applicable Interventional Results available

Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)

NCT01231633
View directory record Official record
Conditions
Macular Edema, Central Retinal Vein Occlusion
Interventions
Ozurdex, Avastin
Drug
Lead sponsor
Long Island Vitreoretinal Consultants
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
4
States / cities
Toms River, New Jersey • Great Neck, New York • Hauppauge, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Oct 24, 2026, 5:11 PM EDT
Completed Phase 2 Interventional Results available

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO

NCT02303184
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
4 mg CLS-TA, Sham, IVT aflibercept
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
14
States / cities
Phoenix, Arizona • Beverly Hills, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Oct 24, 2026, 5:11 PM EDT
Completed Phase 1 Interventional

Intra-arterial Thrombolysis for Severe Recent Central Retinal Vein Occlusion

NCT01581411
View directory record Official record
Conditions
Central Retinal Vein Occlusion
Interventions
Tissue Plasminogen Activator
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 90 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Oct 24, 2026, 5:11 PM EDT
Terminated Phase 4 Interventional Results available

Calf Deep Vein Thrombosis Treatment Trial

NCT03590743
View directory record Official record
Conditions
Deep Vein Thrombosis
Interventions
Apixaban, Placebo
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
3
States / cities
Rochester, Minnesota • Eau Claire, Wisconsin • La Crosse, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Oct 24, 2026, 5:11 PM EDT
Completed Phase 3 Interventional Results available

The SOX Trial: Compression Stockings to Prevent the Post-Thrombotic Syndrome

NCT00143598
View directory record Official record
Conditions
Deep Venous Thrombosis
Interventions
Knee-length, graduated elastic compression stocking, Knee-length, placebo stocking
Device
Lead sponsor
Sir Mortimer B. Davis - Jewish General Hospital
Other
Eligibility
18 Years and older
Enrollment
806 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
3
States / cities
Detroit, Michigan • Durham, North Carolina • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 18, 2014 · Synced Oct 24, 2026, 5:11 PM EDT
Completed No phase listed Observational

Retrospective Study of the Safety and Efficacy of Patients With RVO in Subjects Who Completed Parent Study CLS1003-201

NCT02956330
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
Not listed
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 20, 2019 · Synced Oct 24, 2026, 5:11 PM EDT
Completed Phase 3 Interventional

PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)

NCT00182143
View directory record Official record
Conditions
Critical Illness, Deep Venous Thrombosis
Interventions
LMWH (Fragmin, dalteparin), Unfractionated Heparin
Drug
Lead sponsor
McMaster University
Other
Eligibility
18 Years and older
Enrollment
3,659 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
4
States / cities
Rochester, Minnesota • St Louis, Missouri • Providence, Rhode Island + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2011 · Synced Oct 24, 2026, 5:11 PM EDT
Not listed No phase listed Observational

Platelet FcGammaRIIa and Risk of Venous Thromboembolism in Cancer

NCT05240508
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Not listed
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Oct 24, 2026, 5:11 PM EDT
Terminated Phase 3 Interventional Results available

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion

NCT03810313
View directory record Official record
Conditions
Central Retinal Vein Occlusion
Interventions
Brolucizumab 6 mg, Aflibercept 2 mg, Sham injection
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
30
States / cities
Phoenix, Arizona • La Jolla, California • Mountain View, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Oct 24, 2026, 5:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of MK-2060 in Healthy Participants (MK-2060-016)

NCT06582602
View directory record Official record
Conditions
Venous Thrombosis
Interventions
MK-2060, Placebo
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Miami, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 24, 2026, 5:11 PM EDT
Terminated Not applicable Interventional Results available

Comparison of Arixtra vs. Lovenox to Prevent Blood Clots in Medically Ill Patients

NCT00521885
View directory record Official record
Conditions
Venous Thrombosis
Interventions
Arixtra (Fondaparinox) 2.5 mg SC Daily, Lovenox 40mg SC Daily
Drug
Lead sponsor
Lehigh Valley Hospital
Other
Eligibility
40 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 24, 2026, 5:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About How Safe BAY3018250 is and What Happens to it in Healthy Japanese Men and Adult Participants Aged 18 to 55 Years

NCT06562985
View directory record Official record
Conditions
Acute Venous and Arterial Thrombotic and Thromboembolic Events, Healthy Volunteers
Interventions
BAY3018250 Dose 1, Placebo, BAY3018250 Dose 2 infusion, BAY3018250 Dose 2 injection
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Los Alamitos, California
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Oct 24, 2026, 5:11 PM EDT
Completed Not applicable Interventional Results available

Deep Vein Thrombosis (DVT) Prevention in Total Hip Arthroplasty: Continuous Enhanced Circulation Therapy (CECT) Versus Low Molecular Weight Heparin (LMWH)

NCT00358735
View directory record Official record
Conditions
Deep Vein Thrombosis of Lower Limb, Pulmonary Embolism (PE), Bleeding
Interventions
ActiveCare CECT device, Enoxaparin
Device · Drug
Lead sponsor
Medical Compression Systems
Industry
Eligibility
18 Years and older
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
9
States / cities
La Jolla, California • Loma Linda, California • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2014 · Synced Oct 24, 2026, 5:11 PM EDT
Completed No phase listed Observational

Predicting Bleeding Risk on Anticoagulant Therapy for Venous Thromboembolism

NCT00788736
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Not listed
Lead sponsor
Ottawa Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
2,537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
2
States / cities
Burlington, Massachusetts • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Oct 24, 2026, 5:11 PM EDT
Completed Not applicable Interventional

The Incidence of Perioperative Deep Venous Thromboses of the Lower Extremities

NCT01300832
View directory record Official record
Conditions
Perioperative DVTs
Interventions
Duplex scan of lower extremities
Procedure
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Oct 24, 2026, 5:11 PM EDT
Completed Phase 2Phase 3 Interventional Results available

To Study the Effectiveness and Safety of Niacin and a Topical Steroid Eye Drop to Treat Retinal Vein Occlusions

NCT00493064
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
Nicotinic acid, Prednisolone acetate
Drug
Lead sponsor
Palo Alto Medical Foundation
Other
Eligibility
Not listed
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 21, 2018 · Synced Oct 24, 2026, 5:11 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bedside Ultrasound in the Assessment of Deep Venous Thrombosis: Effectiveness of In-Person Versus Online Instruction

NCT03573492
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolism
Interventions
Education
Other
Lead sponsor
Mercy Health Ohio
Other
Eligibility
Not listed
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Youngstown, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 1, 2019 · Synced Oct 24, 2026, 5:11 PM EDT
Completed Phase 3 Interventional

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery

NCT00697099
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Semuloparin sodium, Enoxaparin sodium, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
2,326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 24, 2026, 5:11 PM EDT
Terminated Phase 4 Interventional Results available

Aspirin and Enoxaparin for VTE in Trauma

NCT02396732
View directory record Official record
Conditions
Venous Thromboembolism, Thromboprophylaxis, Trauma
Interventions
Aspirin, Enoxaparin
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 24, 2026, 5:11 PM EDT
Completed No phase listed Observational

Predicting the Safety and Effectiveness of Inferior Vena Cava Filters

NCT02381509
View directory record Official record
Conditions
Pulmonary Embolism, Deep Vein Thrombosis
Interventions
IVC Filter
Device
Lead sponsor
Carelon Research
Other
Eligibility
18 Years and older
Enrollment
1,428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
53
States / cities
Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Oct 24, 2026, 5:11 PM EDT